Literature DB >> 23006519

Quantitative evaluation of the disintegration of orally rapid disintegrating tablets by X-ray computed tomography.

Makoto Otsuka1, Azusa Yamanaka, Tomohiro Uchino, Kuniko Otsuka, Kiyomi Sadamoto, Hiroyuki Ohshima.   

Abstract

To measure the rapid disintegration of Oral Disintegrating Tablets (ODT), a new test (XCT) was developed using X-ray computing tomography (X-ray CT). Placebo ODT, rapid disintegration candy (RDC) and Gaster®-D-Tablets (GAS) were used as model samples. All these ODTs were used to measure oral disintegration time (DT) in distilled water at 37±2°C by XCT. DTs were affected by the width of mesh screens, and degree to which the tablet holder vibrated from air bubbles. An in-vivo tablet disintegration test was performed for RDC using 11 volunteers. DT by the in-vivo method was significantly longer than that using the conventional tester. The experimental conditions for XCT such as the width of the mesh screen and degree of vibration were adjusted to be consistent with human DT values. Since DTs by the XCT method were almost the same as the human data, this method was able to quantitatively evaluate the rapid disintegration of ODT under the same conditions as inside the oral cavity. The DTs of four commercially available ODTs were comparatively evaluated by the XCT method, conventional tablet disintegration test and in-vivo method.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23006519

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  2 in total

Review 1.  In Vitro and In Vivo Test Methods for the Evaluation of Gastroretentive Dosage Forms.

Authors:  Felix Schneider; Mirko Koziolek; Werner Weitschies
Journal:  Pharmaceutics       Date:  2019-08-16       Impact factor: 6.321

2.  Taking the lead from our colleagues in medical education: the use of images of the in-vivo setting in teaching concepts of pharmaceutical science.

Authors:  Louise E Curley; Julia Kennedy; Jordan Hinton; Ali Mirjalili; Darren Svirskis
Journal:  J Pharm Policy Pract       Date:  2017-07-17
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.